{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:02:28Z","timestamp":1790730148050,"version":"4.1.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19H03444"],"award-info":[{"award-number":["JP19H03444"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00432-020-03438-w","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T19:02:30Z","timestamp":1605985350000},"page":"1499-1518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor"],"prefix":"10.1007","volume":"147","author":[{"given":"Yuichi","family":"Shibui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-1182","authenticated-orcid":false,"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,21]]},"reference":[{"key":"3438_CR1","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1172\/JCI33816","volume":"119","author":"WM Abuzeid","year":"2009","unstructured":"Abuzeid WM, Jiang X, Shi G et al (2009) Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest 119:1974\u20131985. https:\/\/doi.org\/10.1172\/JCI33816","journal-title":"J Clin Invest"},{"key":"3438_CR2","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1002\/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO;2-U","volume":"41","author":"JB Beckwith","year":"1978","unstructured":"Beckwith JB, Palmer NF (1978) Histopathology and prognosis of Wilms tumor results from the first National Wilms\u2019 tumor study. Cancer 41:1937\u20131948. https:\/\/doi.org\/10.1002\/1097-0142(197805)41:5%3c1937::AID-CNCR2820410538%3e3.0.CO;2-U","journal-title":"Cancer"},{"key":"3438_CR3","first-page":"74","volume":"59","author":"JA Biegel","year":"1999","unstructured":"Biegel JA, Zhou JY, Rorke LB et al (1999) Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59:74\u201379","journal-title":"Cancer Res"},{"key":"3438_CR4","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1158\/0008-5472.CAN-10-0545","volume":"70","author":"JR Carr","year":"2010","unstructured":"Carr JR, Park HJ, Wang Z et al (2010) FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70:5054\u20135063. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0545","journal-title":"Cancer Res"},{"key":"3438_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1200\/JCO.2008.18.7724","volume":"27","author":"SN Chi","year":"2009","unstructured":"Chi SN, Zimmerman MA, Yao X et al (2009) Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 27:385\u2013389. https:\/\/doi.org\/10.1200\/JCO.2008.18.7724","journal-title":"J Clin Oncol"},{"key":"3438_CR6","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-05-0493","volume":"5","author":"D Chirnomas","year":"2006","unstructured":"Chirnomas D, Taniguchi T, De La Vega M et al (2006) Chemosensitization to cisplatin by inhibitors of the Fanconi anemia\/BRCA pathway. Mol Cancer Ther 5:952\u2013961. https:\/\/doi.org\/10.1158\/1535-7163.MCT-05-0493","journal-title":"Mol Cancer Ther"},{"key":"3438_CR7","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.18632\/oncotarget.2957","volume":"6","author":"WT Chiu","year":"2015","unstructured":"Chiu WT, Huang YF, Tsai HY et al (2015) FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget 6:2349\u20132365. https:\/\/doi.org\/10.18632\/oncotarget.2957","journal-title":"Oncotarget"},{"key":"3438_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0054556","volume":"8","author":"L Christensen","year":"2013","unstructured":"Christensen L, Joo J, Lee S et al (2013) FOXM1 is an oncogenic mediator in Ewing sarcoma. PLoS ONE 8:1\u20137. https:\/\/doi.org\/10.1371\/journal.pone.0054556","journal-title":"PLoS ONE"},{"key":"3438_CR9","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.cellsig.2015.09.013","volume":"27","author":"GN de Moraes","year":"2015","unstructured":"de Moraes GN, Delbue D, Silva KL et al (2015) FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance. Cell Signal 27:2496\u20132505. https:\/\/doi.org\/10.1016\/j.cellsig.2015.09.013","journal-title":"Cell Signal"},{"key":"3438_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/cdd.2017.172","volume":"25","author":"K Engeland","year":"2018","unstructured":"Engeland K (2018) Cell cycle arrest through indirect transcriptional repression by p53: i have a DREAM. Cell Death Differ 25:114\u2013132. https:\/\/doi.org\/10.1038\/cdd.2017.172","journal-title":"Cell Death Differ"},{"key":"3438_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/gerona\/glu019","volume":"70","author":"R Gao","year":"2015","unstructured":"Gao R, Singh R, Kaul Z et al (2015) Targeting of DNA damage signaling pathway induced senescence and reduced migration of cancer cells. J Gerontol Ser A Biol Sci Med Sci 70:701\u2013713. https:\/\/doi.org\/10.1093\/gerona\/glu019","journal-title":"J Gerontol Ser A Biol Sci Med Sci"},{"key":"3438_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1517\/14728222.12.6.663","volume":"12","author":"AL Gartel","year":"2008","unstructured":"Gartel AL (2008) FoxM1 inhibitors as potential anticancer drugs. Expert Opin Ther Targets 12:663\u2013665","journal-title":"Expert Opin Ther Targets"},{"key":"3438_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1615\/CritRevOncog.2015013566","volume":"20","author":"JI Geller","year":"2015","unstructured":"Geller JI, Roth JJ, Biegel JA (2015) Biology and treatment of rhabdoid tumor. Crit Rev Oncog 20:199\u2013216. https:\/\/doi.org\/10.1615\/CritRevOncog.2015013566","journal-title":"Crit Rev Oncog"},{"key":"3438_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2012.00114","volume":"2","author":"KF Ginn","year":"2012","unstructured":"Ginn KF, Gajjar A (2012) Atypical teratoid rhabdoid tumor: current therapy and future directions. Front Oncol 2:1\u201313. https:\/\/doi.org\/10.3389\/fonc.2012.00114","journal-title":"Front Oncol"},{"key":"3438_CR15","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1091\/mbc.E13-05-0264","volume":"24","author":"GD Grant","year":"2013","unstructured":"Grant GD, Brooks L, Zhang X et al (2013) Identification of cell cycle-regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors. Mol Biol Cell 24:3634\u20133650. https:\/\/doi.org\/10.1091\/mbc.E13-05-0264","journal-title":"Mol Biol Cell"},{"key":"3438_CR16","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1093\/hmg\/10.20.2253","volume":"10","author":"M Grompe","year":"2001","unstructured":"Grompe M (2001) Fanconi anemia and DNA repair. Hum Mol Genet 10:2253\u20132259. https:\/\/doi.org\/10.1093\/hmg\/10.20.2253","journal-title":"Hum Mol Genet"},{"key":"3438_CR17","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1186\/s12885-019-6443-1","volume":"19","author":"C Gu","year":"2019","unstructured":"Gu C, Jing X, Holman C et al (2019) Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer 19:1238. https:\/\/doi.org\/10.1186\/s12885-019-6443-1","journal-title":"BMC Cancer"},{"key":"3438_CR18","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.4161\/cc.8.12.8708","volume":"8","author":"M Halasi","year":"2009","unstructured":"Halasi M, Gartel AL (2009) A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle 8:1966\u20131967. https:\/\/doi.org\/10.4161\/cc.8.12.8708","journal-title":"Cell Cycle"},{"key":"3438_CR19","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/PAS.0b013e3182196a39","volume":"35","author":"M Hasselblatt","year":"2011","unstructured":"Hasselblatt M, Gesk S, Oyen F et al (2011) Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid\/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol 35:933\u2013935. https:\/\/doi.org\/10.1097\/PAS.0b013e3182196a39","journal-title":"Am J Surg Pathol"},{"key":"3438_CR20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.dnarep.2007.02.006","volume":"6","author":"T Helleday","year":"2007","unstructured":"Helleday T, Lo J, van Gent DC, Engelward BP (2007) DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 6:923\u2013935. https:\/\/doi.org\/10.1016\/j.dnarep.2007.02.006","journal-title":"DNA Repair (Amst)"},{"key":"3438_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4776-9","volume":"18","author":"V Ho","year":"2018","unstructured":"Ho V, Chung L, Singh A et al (2018) Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis. BMC Cancer 18:1\u201311. https:\/\/doi.org\/10.1186\/s12885-018-4776-9","journal-title":"BMC Cancer"},{"key":"3438_CR22","doi-asserted-by":"publisher","first-page":"e2659","DOI":"10.1038\/cddis.2017.53","volume":"8","author":"Y Hou","year":"2017","unstructured":"Hou Y, Zhu Q, Li Z et al (2017) The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. Cell Death Dis 8:e2659\u2013e2711. https:\/\/doi.org\/10.1038\/cddis.2017.53","journal-title":"Cell Death Dis"},{"key":"3438_CR23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.7150\/jca.14461","volume":"7","author":"T Ito","year":"2016","unstructured":"Ito T, Kohashi K, Yamada Y et al (2016a) Prognostic significance of Forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in angiosarcoma. J Cancer 7:823\u2013830. https:\/\/doi.org\/10.7150\/jca.14461","journal-title":"J Cancer"},{"key":"3438_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/his.12909","volume":"69","author":"T Ito","year":"2016","unstructured":"Ito T, Kohashi K, Yamada Y et al (2016b) Prognostic significance of forkhead box M1 (FoxM1) expression and antitumour effect of FoxM1 inhibition in melanoma. Histopathology 69:63\u201371. https:\/\/doi.org\/10.1111\/his.12909","journal-title":"Histopathology"},{"key":"3438_CR25","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/0008-5472.CAN-05-3138","volume":"66","author":"TV Kalin","year":"2006","unstructured":"Kalin TV, Wang I-C, Ackerson TJ, Major ML, Detrisac CJ, Kalinichenko VV, Alexander LRHC (2006) Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 66:1712\u20131720","journal-title":"Cancer Res"},{"key":"3438_CR26","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1101\/gad.1200704","volume":"18","author":"VV Kalinichenko","year":"2004","unstructured":"Kalinichenko VV, Major ML, Wang X et al (2004) Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 18:830\u2013850. https:\/\/doi.org\/10.1101\/gad.1200704","journal-title":"Genes Dev"},{"key":"3438_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.121583","volume":"3","author":"I Khan","year":"2018","unstructured":"Khan I, Halasi M, Patel A et al (2018) FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI insight 3:1\u201317. https:\/\/doi.org\/10.1172\/jci.insight.121583","journal-title":"JCI insight"},{"key":"3438_CR28","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1038\/onc.2013.457","volume":"33","author":"P Khongkow","year":"2014","unstructured":"Khongkow P, Karunarathna U, Khongkow M et al (2014) FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene 33:4144\u20134155. https:\/\/doi.org\/10.1038\/onc.2013.457","journal-title":"Oncogene"},{"key":"3438_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.cancergen.2014.04.004","volume":"207","author":"KH Kim","year":"2014","unstructured":"Kim KH, Roberts CWM (2014) Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genet 207:365\u2013372. https:\/\/doi.org\/10.1016\/j.cancergen.2014.04.004","journal-title":"Cancer Genet"},{"key":"3438_CR30","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1158\/0008-5472.CAN-05-3003","volume":"66","author":"IM Kim","year":"2006","unstructured":"Kim IM, Ackerson T, Ramakrishna S et al (2006) The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 66:2153\u20132161. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3003","journal-title":"Cancer Res"},{"key":"3438_CR31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.21873\/anticanres.11420","volume":"37","author":"H Komatsu","year":"2017","unstructured":"Komatsu H, Masuda T, Iguchi T et al (2017) Clinical significance of fancd2 gene expression and its association with tumor progression in hepatocellular carcinoma. Anticancer Res 37:1083\u20131090. https:\/\/doi.org\/10.21873\/anticanres.11420","journal-title":"Anticancer Res"},{"key":"3438_CR32","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1007\/s13277-015-4351-9","volume":"37","author":"M Kuda","year":"2016","unstructured":"Kuda M, Kohashi K, Yamada Y et al (2016) FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target. Tumour Biol 37:5213\u20135223. https:\/\/doi.org\/10.1007\/s13277-015-4351-9","journal-title":"Tumour Biol"},{"key":"3438_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1245\/s10434-011-2043-2","volume":"19","author":"K-T Kuo","year":"2012","unstructured":"Kuo K-T, Chou T-Y, Hsu H-S et al (2012) Prognostic significance of NBS1 and snail expression in esophageal squamous cell carcinoma. Ann Surg Oncol 19:549\u2013557. https:\/\/doi.org\/10.1245\/s10434-011-2043-2","journal-title":"Ann Surg Oncol"},{"key":"3438_CR34","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1158\/1535-7163.MCT-08-0188","volume":"7","author":"JMM Kwok","year":"2008","unstructured":"Kwok JMM, Myatt SS, Marson CM et al (2008) Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther 7:2022\u20132032. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0188","journal-title":"Mol Cancer Ther"},{"key":"3438_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/1541-7786.MCR-09-0432","volume":"8","author":"JMM Kwok","year":"2010","unstructured":"Kwok JMM, Peck B, Monteiro LJ et al (2010) FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 8:24\u201334. https:\/\/doi.org\/10.1158\/1541-7786.MCR-09-0432","journal-title":"Mol Cancer Res"},{"key":"3438_CR36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/ncb1217","volume":"7","author":"J Laoukili","year":"2005","unstructured":"Laoukili J, Kooistra MRH, Br\u00e1s A et al (2005) FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7:126\u2013136. https:\/\/doi.org\/10.1038\/ncb1217","journal-title":"Nat Cell Biol"},{"key":"3438_CR37","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.3892\/or.2018.6336","volume":"39","author":"I Leon-Galicia","year":"2018","unstructured":"Leon-Galicia I, Diaz-Chavez J, Albino-Sanchez ME et al (2018) Resveratrol decreases Rad51 expression and sensitizes cisplatin-resistant MCF-7 breast cancer cells. Oncol Rep 39:3025\u20133033. https:\/\/doi.org\/10.3892\/or.2018.6336","journal-title":"Oncol Rep"},{"key":"3438_CR38","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5483\/BMBRep.2019.52.3.249","volume":"52","author":"D Li","year":"2019","unstructured":"Li D, Ye L, Lei Y et al (2019) Downregulation of FoxM1 sensitizes nasopharyngeal carcinoma cells to cisplatin via inhibition of MRN-ATM-mediated DNA repair. BMB Rep 52:208\u2013213. https:\/\/doi.org\/10.5483\/BMBRep.2019.52.3.249","journal-title":"BMB Rep"},{"key":"3438_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms12124","volume":"7","author":"CC Liang","year":"2016","unstructured":"Liang CC, Li Z, Lopez-Martinez D et al (2016) The FANCD2-FANCI complex is recruited to DNA interstrand crosslinks before monoubiquitination of FANCD2. Nat Commun 7:1\u201310. https:\/\/doi.org\/10.1038\/ncomms12124","journal-title":"Nat Commun"},{"key":"3438_CR40","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1158\/0008-5472.CAN-05-2912","volume":"66","author":"M Liu","year":"2006","unstructured":"Liu M, Dai B, Kang SH et al (2006) FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 66:3593\u20133602. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2912","journal-title":"Cancer Res"},{"key":"3438_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4149\/neo_2015_008","volume":"62","author":"Y Liu","year":"2015","unstructured":"Liu Y, Chen X, Gu Y et al (2015) FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK\/mitochondrial pathway. Neoplasma 62:61\u201371. https:\/\/doi.org\/10.4149\/neo_2015_008","journal-title":"Neoplasma"},{"key":"3438_CR42","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1042\/CS20180816","volume":"133","author":"C Liu","year":"2019","unstructured":"Liu C, Shi J, Li Q et al (2019) STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer. Clin Sci 133:645\u2013663. https:\/\/doi.org\/10.1042\/CS20180816","journal-title":"Clin Sci"},{"key":"3438_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-1-60761-738-9_6","volume":"647","author":"RYM Ma","year":"2010","unstructured":"Ma RYM, Tong THK, Leung WY, Yao KM (2010) Raf\/MEK\/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1. Methods Mol Biol 647:113\u2013123. https:\/\/doi.org\/10.1007\/978-1-60761-738-9_6","journal-title":"Methods Mol Biol"},{"key":"3438_CR44","doi-asserted-by":"publisher","first-page":"25167","DOI":"10.1074\/jbc.M603906200","volume":"281","author":"PA Madureira","year":"2006","unstructured":"Madureira PA, Varshochi R, Constantinidou D et al (2006) The forkhead box M1 protein regulates the transcription of the estrogen receptor \u03b1 in breast cancer cells. J Biol Chem 281:25167\u201325176. https:\/\/doi.org\/10.1074\/jbc.M603906200","journal-title":"J Biol Chem"},{"key":"3438_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2542-4","volume":"16","author":"A Maekawa","year":"2016","unstructured":"Maekawa A, Kohashi K, Kuda M et al (2016) Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas. BMC Cancer 16:1\u201312. https:\/\/doi.org\/10.1186\/s12885-016-2542-4","journal-title":"BMC Cancer"},{"key":"3438_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/cas.12846","volume":"107","author":"A Maekawa","year":"2016","unstructured":"Maekawa A, Kohashi K, Setsu N et al (2016) Expression of Forkhead box M1 in soft tissue leiomyosarcoma: clinicopathologic and in vitro study using a newly established cell line. Cancer Sci 107:95\u2013102. https:\/\/doi.org\/10.1111\/cas.12846","journal-title":"Cancer Sci"},{"key":"3438_CR47","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1128\/mcb.24.7.2649-2661.2004","volume":"24","author":"ML Major","year":"2004","unstructured":"Major ML, Lepe R, Costa RH (2004) Forkhead Box M1B transcriptional activity requires binding of Cdk-Cyclin complexes for phosphorylation-dependent recruitment of p300\/CBP coactivators. Mol Cell Biol 24:2649\u20132661. https:\/\/doi.org\/10.1128\/mcb.24.7.2649-2661.2004","journal-title":"Mol Cell Biol"},{"key":"3438_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-012414-040445","volume":"10","author":"J Masliah-Planchon","year":"2015","unstructured":"Masliah-Planchon J, Bi\u00e8che I, Guinebreti\u00e8re J-M et al (2015) SWI\/SNF chromatin remodeling and human malignancies. Annu Rev Pathol Mech Dis 10:145\u2013171","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"3438_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ebiom.2019.10.062","volume":"50","author":"DS Metselaar","year":"2019","unstructured":"Metselaar DS, Meel MH, Benedict B et al (2019) Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. EBioMedicine 50:81\u201392. https:\/\/doi.org\/10.1016\/j.ebiom.2019.10.062","journal-title":"EBioMedicine"},{"key":"3438_CR50","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1038\/onc.2012.491","volume":"32","author":"LJ Monteiro","year":"2013","unstructured":"Monteiro LJ, Khongkow P, Kongsema M et al (2013) The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene 32:4634\u20134645. https:\/\/doi.org\/10.1038\/onc.2012.491","journal-title":"Oncogene"},{"key":"3438_CR51","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/ncb879","volume":"4","author":"K Nakanishi","year":"2002","unstructured":"Nakanishi K, Taniguchi T, Ranganathan V et al (2002) Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell Biol 4:913\u2013920. https:\/\/doi.org\/10.1038\/ncb879","journal-title":"Nat Cell Biol"},{"key":"3438_CR52","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/cas.12652","volume":"106","author":"S Nakashima","year":"2015","unstructured":"Nakashima S, Kobayashi S, Nagano H et al (2015) BRCA\/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. Cancer Sci 106:584\u2013591. https:\/\/doi.org\/10.1111\/cas.12652","journal-title":"Cancer Sci"},{"key":"3438_CR53","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1349-7006.2001.tb01091.x","volume":"92","author":"T Narita","year":"2001","unstructured":"Narita T, Taga T, Sugita K et al (2001) The autocrine loop of epidermal growth factor receptor-epidermal growth factor\/transforming growth factor-\u03b1 in malignant rhabdoid tumor cell lines: heterogeneity of autocrine mechanism in TTC549. Japanese J Cancer Res 92:269\u2013278. https:\/\/doi.org\/10.1111\/j.1349-7006.2001.tb01091.x","journal-title":"Japanese J Cancer Res"},{"key":"3438_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18081804","volume":"18","author":"M Nepal","year":"2017","unstructured":"Nepal M, Che R, Ma C et al (2017) FANCD2 and DNA damage. Int J Mol Sci 18:1\u20139. https:\/\/doi.org\/10.3390\/ijms18081804","journal-title":"Int J Mol Sci"},{"key":"3438_CR55","doi-asserted-by":"publisher","first-page":"15042","DOI":"10.1021\/ja0552803","volume":"127","author":"KC Nicolaou","year":"2005","unstructured":"Nicolaou KC, Zak M, Rahimipour S et al (2005) Discovery of a biologically active thiostrepton fragment. J Am Chem Soc 127:15042\u201315044. https:\/\/doi.org\/10.1021\/ja0552803","journal-title":"J Am Chem Soc"},{"key":"3438_CR56","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1245\/s10434-012-2680-0","volume":"20","author":"K Okada","year":"2013","unstructured":"Okada K, Fujiwara Y, Takahashi T et al (2013) Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol 20:1035\u20131043. https:\/\/doi.org\/10.1245\/s10434-012-2680-0","journal-title":"Ann Surg Oncol"},{"key":"3438_CR57","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4161\/cc.10.10.15617","volume":"10","author":"K Palle","year":"2011","unstructured":"Palle K, Vaziri C (2011) Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA topoisomerase 1 inhibition. Cell Cycle 10:1625\u20131638. https:\/\/doi.org\/10.4161\/cc.10.10.15617","journal-title":"Cell Cycle"},{"key":"3438_CR58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/emmm.201000107","volume":"3","author":"HJ Park","year":"2011","unstructured":"Park HJ, Gusarova G, Wang Z et al (2011) Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med 3:21\u201334. https:\/\/doi.org\/10.1002\/emmm.201000107","journal-title":"EMBO Mol Med"},{"key":"3438_CR59","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/carcin\/bgs167","volume":"33","author":"YY Park","year":"2012","unstructured":"Park YY, Jung SY, Jennings NB et al (2012) FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33:1843\u20131853. https:\/\/doi.org\/10.1093\/carcin\/bgs167","journal-title":"Carcinogenesis"},{"key":"3438_CR60","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10565-017-9381-1","volume":"33","author":"WX Peng","year":"2017","unstructured":"Peng WX, Han X, Zhang CL et al (2017) FoxM1-mediated RFC5 expression promotes temozolomide resistance. Cell Biol Toxicol 33:527\u2013537. https:\/\/doi.org\/10.1007\/s10565-017-9381-1","journal-title":"Cell Biol Toxicol"},{"key":"3438_CR61","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1593\/neo.04277","volume":"6","author":"C Pilarsky","year":"2004","unstructured":"Pilarsky C, Wenzig M, Specht T et al (2004) Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 6:744\u2013750. https:\/\/doi.org\/10.1593\/neo.04277","journal-title":"Neoplasia"},{"key":"3438_CR62","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1158\/0008-5472.CAN-11-0640","volume":"71","author":"P Raychaudhuri","year":"2011","unstructured":"Raychaudhuri P, Park HJ (2011) FoxM1: a master regulator of tumor metastasis. Cancer Res 71:4329\u20134333. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0640","journal-title":"Cancer Res"},{"key":"3438_CR63","doi-asserted-by":"publisher","first-page":"36996","DOI":"10.18632\/oncotarget.16940","volume":"8","author":"L Ren","year":"2017","unstructured":"Ren L, Chen L, Wu W et al (2017) Potential biomarkers of DNA replication stress in cancer. Oncotarget 8:36996\u201337008. https:\/\/doi.org\/10.18632\/oncotarget.16940","journal-title":"Oncotarget"},{"key":"3438_CR64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrc1273","volume":"4","author":"CWM Roberts","year":"2004","unstructured":"Roberts CWM, Orkin SH (2004) The SWI\/SNF complex\u2014chromatin and cancer. Nat Rev Cancer 4:133\u2013142. https:\/\/doi.org\/10.1038\/nrc1273","journal-title":"Nat Rev Cancer"},{"key":"3438_CR65","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5483\/BMBRep.2018.51.2.222","volume":"51","author":"YG Roh","year":"2018","unstructured":"Roh YG, Mun MH, Jeong MS et al (2018) Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1. BMB Rep 51:98\u2013103. https:\/\/doi.org\/10.5483\/BMBRep.2018.51.2.222","journal-title":"BMB Rep"},{"key":"3438_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12061417","volume":"12","author":"YG Roh","year":"2020","unstructured":"Roh YG, Mun JY, Kim SK et al (2020) Fanconi anemia pathway activation by foxm1 is critical to bladder cancer recurrence and anticancer drug resistance. Cancers (Basel) 12:1\u201320. https:\/\/doi.org\/10.3390\/cancers12061417","journal-title":"Cancers (Basel)"},{"key":"3438_CR67","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ajhg.2010.01.013","volume":"86","author":"R Schneppenheim","year":"2010","unstructured":"Schneppenheim R, Fr\u00fchwald MC, Gesk S et al (2010) Germline nonsense mutation and somatic inactivation of SMARCA4\/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 86:279\u2013284. https:\/\/doi.org\/10.1016\/j.ajhg.2010.01.013","journal-title":"Am J Hum Genet"},{"key":"3438_CR68","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.18632\/aging.100988","volume":"8","author":"A Smirnov","year":"2016","unstructured":"Smirnov A, Panatta E, Lena AM et al (2016) FOXM1 regulates proliferation, senescence and oxidative stress in keratinocytes and cancer cells. Aging (Albany NY) 8:1384\u20131397. https:\/\/doi.org\/10.18632\/aging.100988","journal-title":"Aging (Albany NY)"},{"key":"3438_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-04223-5","volume":"7","author":"WP Su","year":"2017","unstructured":"Su WP, Ho YC, Wu CK et al (2017) Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways. Sci Rep 7:1\u201315. https:\/\/doi.org\/10.1038\/s41598-017-04223-5","journal-title":"Sci Rep"},{"key":"3438_CR70","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/pbc.22285","volume":"54","author":"I Sultan","year":"2010","unstructured":"Sultan I, Qaddoumi I, Rodriguez-Galindo C et al (2010) Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors. Pediatr Blood Cancer 54:35\u201340. https:\/\/doi.org\/10.1002\/pbc.22285","journal-title":"Pediatr Blood Cancer"},{"key":"3438_CR71","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1128\/mcb.01068-06","volume":"27","author":"Y Tan","year":"2007","unstructured":"Tan Y, Raychaudhuri P, Costa RH (2007) Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol 27:1007\u20131016. https:\/\/doi.org\/10.1128\/mcb.01068-06","journal-title":"Mol Cell Biol"},{"key":"3438_CR72","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0092-8674(02)00747-X","volume":"109","author":"T Taniguchi","year":"2002","unstructured":"Taniguchi T, Garcia-Higuera I, Xu B et al (2002) Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109:459\u2013472. https:\/\/doi.org\/10.1016\/S0092-8674(02)00747-X","journal-title":"Cell"},{"key":"3438_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-017-0536-y","volume":"36","author":"RA Tassi","year":"2017","unstructured":"Tassi RA, Todeschini P, Siegel ER et al (2017) FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. J Exp Clin Cancer Res 36:1\u201318. https:\/\/doi.org\/10.1186\/s13046-017-0536-y","journal-title":"J Exp Clin Cancer Res"},{"key":"3438_CR74","first-page":"4773","volume":"62","author":"MT Teh","year":"2002","unstructured":"Teh MT, Wong ST, Neill GW et al (2002) FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 62:4773\u20134780","journal-title":"Cancer Res"},{"key":"3438_CR75","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.18632\/oncotarget.23513","volume":"9","author":"L Tian","year":"2018","unstructured":"Tian L, Zhao Z, Xie L, Zhu JP (2018) MiR-361\u20135p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K\/Akt\/mTOR pathway. Oncotarget 9:4886\u20134896. https:\/\/doi.org\/10.18632\/oncotarget.23513","journal-title":"Oncotarget"},{"key":"3438_CR76","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.1200\/JCO.2004.00.8110","volume":"23","author":"GE Tomlinson","year":"2005","unstructured":"Tomlinson GE, Breslow NE, Dome J et al (2005) Rhabdoid tumor of the kidney in the National Wilms\u2019 Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol 23:7641\u20137645. https:\/\/doi.org\/10.1200\/JCO.2004.00.8110","journal-title":"J Clin Oncol"},{"key":"3438_CR77","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ajpath.2010.10.020","volume":"178","author":"S Uddin","year":"2011","unstructured":"Uddin S, Ahmed M, Hussain A et al (2011) Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol 178:537\u2013547. https:\/\/doi.org\/10.1016\/j.ajpath.2010.10.020","journal-title":"Am J Pathol"},{"key":"3438_CR78","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/pbc.22922","volume":"56","author":"MM van den Heuvel-Eibrink","year":"2011","unstructured":"van den Heuvel-Eibrink MM, van Tinteren H, Rehorst H et al (2011) Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group. Pediatr Blood Cancer 56:733\u2013737. https:\/\/doi.org\/10.1002\/pbc.22922","journal-title":"Pediatr Blood Cancer"},{"key":"3438_CR79","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/28212","volume":"394","author":"I Versteege","year":"1998","unstructured":"Versteege I, Sevenet N, Lange J, Rousseau-Merck M-F, Ambros P, Handgretinger Rt, Airias A, Delattre O (1998) Truncating mutations of hSNF5\/INI1 in aggressive paedeatric cancer. Nature 394:203\u2013206","journal-title":"Nature"},{"key":"3438_CR80","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bbrc.2014.11.039","volume":"457","author":"LY Wan","year":"2015","unstructured":"Wan LY, Deng J, Xiang XJ et al (2015) miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun 457:125\u2013132. https:\/\/doi.org\/10.1016\/j.bbrc.2014.11.039","journal-title":"Biochem Biophys Res Commun"},{"key":"3438_CR81","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1078-0432","volume":"20","author":"X Wang","year":"2014","unstructured":"Wang X, Haswell JR, CMWR (2014) Molecular pathways: SWI\/SNF(BAF) complexes are frequently mutated in cancer\u2014mechanisms and potential therapeutic insights. Clin Cancer Res 20:21\u201327. https:\/\/doi.org\/10.1158\/1078-0432","journal-title":"Clin Cancer Res"},{"key":"3438_CR82","doi-asserted-by":"publisher","first-page":"10875","DOI":"10.1128\/mcb.25.24.10875-10894.2005","volume":"25","author":"I-C Wang","year":"2005","unstructured":"Wang I-C, Chen Y-J, Hughes D et al (2005) Forkhead Box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) Ubiquitin Ligase. Mol Cell Biol 25:10875\u201310894. https:\/\/doi.org\/10.1128\/mcb.25.24.10875-10894.2005","journal-title":"Mol Cell Biol"},{"key":"3438_CR83","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1535-7163.MCT-06-0427","volume":"5","author":"Y Wang","year":"2006","unstructured":"Wang Y, Wiltshire T, Senft J et al (2006) Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven. Mol Cancer Ther 5:3153\u20133161. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0427","journal-title":"Mol Cancer Ther"},{"key":"3438_CR84","doi-asserted-by":"publisher","first-page":"8293","DOI":"10.1158\/0008-5472.CAN-07-1265","volume":"67","author":"Z Wang","year":"2007","unstructured":"Wang Z, Banerjee S, Kong D et al (2007) Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 67:8293\u20138300. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1265","journal-title":"Cancer Res"},{"key":"3438_CR85","doi-asserted-by":"publisher","first-page":"20770","DOI":"10.1074\/jbc.M709892200","volume":"283","author":"I-C Wang","year":"2008","unstructured":"Wang I-C, Chen Y-J, Hughes DE et al (2008) FoxM1 regulates transcription of JNK1 to promote the G 1 \/S transition and tumor cell invasiveness. J Biol Chem 283:20770\u201320778. https:\/\/doi.org\/10.1074\/jbc.M709892200","journal-title":"J Biol Chem"},{"key":"3438_CR86","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/00000478-198906000-00001","volume":"13","author":"DA Weeks","year":"1989","unstructured":"Weeks DA, Beckwith JB, Mierau GW, Luckey DW (1989) Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms\u2019 Tumor Study Pathology Center. Am J Surg Pathol 13:439\u2013458","journal-title":"Am J Surg Pathol"},{"key":"3438_CR87","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/IGC.0000000000000969","volume":"27","author":"GL Westhoff","year":"2017","unstructured":"Westhoff GL, Chen Y, Teng NNH (2017) Targeting foxm1 improves cytotoxicity of paclitaxel and cisplatinum in platinum-resistant ovarian cancer. Int J Gynecol Cancer 27:887\u2013894. https:\/\/doi.org\/10.1097\/IGC.0000000000000969","journal-title":"Int J Gynecol Cancer"},{"key":"3438_CR88","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1515\/BC.2007.159","volume":"388","author":"I Wierstra","year":"2007","unstructured":"Wierstra I, Alves J (2007) FOXM1, a typical proliferation-associated transcription factor. Biol Chem 388:1257\u20131274. https:\/\/doi.org\/10.1515\/BC.2007.159","journal-title":"Biol Chem"},{"key":"3438_CR89","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1158\/0008-5472.CAN-04-4059","volume":"65","author":"DR Wonsey","year":"2005","unstructured":"Wonsey DR, Follettie MT (2005) Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 65:5181\u20135189. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-4059","journal-title":"Cancer Res"},{"key":"3438_CR90","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/aps.2010.4","volume":"31","author":"QF Wu","year":"2010","unstructured":"Wu QF, Liu C, Tai MH et al (2010) Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol Sin 31:361\u2013366. https:\/\/doi.org\/10.1038\/aps.2010.4","journal-title":"Acta Pharmacol Sin"},{"key":"3438_CR91","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1093\/carcin\/bgs249","volume":"33","author":"L Xia","year":"2012","unstructured":"Xia L, Mo P, Huang W et al (2012) The TNF-\u03b1\/ROS\/HIF-1-induced upregulation of foxMI expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis 33:2250\u20132259. https:\/\/doi.org\/10.1093\/carcin\/bgs249","journal-title":"Carcinogenesis"},{"key":"3438_CR92","doi-asserted-by":"crossref","unstructured":"Xie T, Geng J, Wang Y, et al (2017) FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10 8:8574\u20138589","DOI":"10.18632\/oncotarget.14351"},{"key":"3438_CR93","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1159\/000369715","volume":"35","author":"K Xu","year":"2015","unstructured":"Xu K, Liu X, Mao X et al (2015) MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem 35:499\u2013515. https:\/\/doi.org\/10.1159\/000369715","journal-title":"Cell Physiol Biochem"},{"key":"3438_CR94","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s12253-014-9776-8","volume":"20","author":"Q Ye","year":"2014","unstructured":"Ye Q, Chen L, Yin X et al (2014) Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathol Oncol Res 20:931\u2013938. https:\/\/doi.org\/10.1007\/s12253-014-9776-8","journal-title":"Pathol Oncol Res"},{"key":"3438_CR95","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-10-1551","volume":"17","author":"J Yu","year":"2011","unstructured":"Yu J, Deshmukh H, Payton JE et al (2011) Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res 17:1924\u20131934. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1551","journal-title":"Clin Cancer Res"},{"key":"3438_CR96","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-12-0039","volume":"18","author":"N Zhang","year":"2012","unstructured":"Zhang N, Wu X, Yang L et al (2012) FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res 18:5961\u20135971. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0039","journal-title":"Clin Cancer Res"},{"key":"3438_CR97","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00109-014-1198-2","volume":"92","author":"JR Zhang","year":"2014","unstructured":"Zhang JR, Lu F, Lu T et al (2014) Inactivation of FoxM1 transcription factor contributes to curcumin-induced inhibition of survival, angiogenesis, and chemosensitivity in acute myeloid leukemia cells. J Mol Med 92:1319\u20131330. https:\/\/doi.org\/10.1007\/s00109-014-1198-2","journal-title":"J Mol Med"},{"key":"3438_CR98","doi-asserted-by":"publisher","first-page":"86134","DOI":"10.18632\/oncotarget.13348","volume":"7","author":"C Zhang","year":"2016","unstructured":"Zhang C, Wang Y, Feng YF et al (2016) Gli1 promotes colorectal cancer metastasis in a Foxm1-dependent manner by activating EMT and PI3k-AKT signaling. Oncotarget 7:86134\u201386147","journal-title":"Oncotarget"},{"key":"3438_CR99","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/abbs\/gmy080","volume":"50","author":"X Zhu","year":"2018","unstructured":"Zhu X, Xue L, Yao Y et al (2018) The FoxM1-ABCC4 axis mediates carboplatin resistance in human retinoblastoma Y-79 cells. Acta Biochim Biophys Sin (Shanghai) 50:914\u2013920. https:\/\/doi.org\/10.1093\/abbs\/gmy080","journal-title":"Acta Biochim Biophys Sin (Shanghai)"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03438-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-020-03438-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03438-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T18:03:48Z","timestamp":1617645828000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-020-03438-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,21]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3438"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03438-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,21]]},"assertion":[{"value":"25 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest in association with the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board at Kyushu University (permission code 29-429,29-625).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}